HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Malignant mesothelioma of pleura — Clinical Guidelines

Overview

Malignant mesothelioma of the pleura is a highly aggressive neoplasm primarily associated with asbestos exposure, characterized by the malignant transformation of mesothelial cells lining the pleural cavity. This condition predominantly affects individuals with a history of occupational or environmental asbestos exposure, typically presenting decades after initial exposure. Given its poor prognosis and limited treatment options, early diagnosis and multidisciplinary management are crucial for improving patient outcomes. Understanding the nuances of surgical techniques, adjuvant therapies, and prognostic factors is essential for clinicians to optimize care in day-to-day practice 1 4 5 6.

Pathophysiology

The pathophysiology of malignant pleural mesothelioma (MPM) involves complex molecular and genetic alterations that lead to uncontrolled proliferation of mesothelial cells. Key events include the inactivation of tumor suppressor genes such as NF2 (neurofibromatosis-2) and alterations in cell cycle regulators like INK4alpha/ARF 5. Chronic inflammation and oxidative stress induced by asbestos fibers trigger DNA damage and genomic instability, promoting mutations and chromosomal aberrations. These genetic changes facilitate epithelial-mesenchymal transition (EMT), enhancing tumor invasiveness and metastatic potential. Additionally, aberrant signaling pathways, such as those involving growth factors and inflammatory cytokines, contribute to tumor growth and resistance to therapy 5 6.

Epidemiology

Malignant pleural mesothelioma has a global incidence that continues to rise, particularly in regions with historical asbestos use. The incidence is estimated to peak over the next two decades due to the latency period between asbestos exposure and disease onset, typically ranging from 30 to 50 years. The disease predominantly affects older adults, with a median age at diagnosis around 60-70 years, and shows a slight male predominance. Geographic variations exist, with higher incidence rates reported in industrialized countries and specific regions with significant asbestos exposure histories. Occupational exposure in industries such as mining, construction, and shipbuilding remains a primary risk factor, although environmental exposure also plays a role 5 6.

Clinical Presentation

Patients with malignant pleural mesothelioma often present with nonspecific symptoms that can delay diagnosis. Common manifestations include dyspnea, chest pain, and pleural effusion, which may be accompanied by weight loss, fatigue, and cough. Atypical presentations can include abdominal pain due to peritoneal involvement or neurological symptoms if there is mediastinal tumor spread. Red-flag features include rapidly progressing symptoms, significant weight loss, and signs of advanced disease such as jaundice or superior vena cava syndrome. Early recognition of these symptoms is critical for timely intervention 5.

Diagnosis

The diagnostic approach for malignant pleural mesothelioma involves a combination of clinical evaluation, imaging, and histopathological confirmation. Key steps include:

Clinical Evaluation: Detailed history focusing on asbestos exposure and symptomatology.

Imaging: Chest CT and MRI to assess pleural thickening, nodules, and effusions.

Thoracoscopy: Preferred method for obtaining tissue samples.

Histopathology: Definitive diagnosis requires immunohistochemical staining to differentiate mesothelioma from other pleural malignancies.

Specific Criteria and Tests:

Biopsy: Thoracoscopic biopsy with pleural fluid cytology.

Immunohistochemistry: Positive markers include calretinin, WT-1, and D2-40; negative for BerEp4 and CK5/6.

Imaging Criteria: CT findings suggestive of mesothelioma include diffuse pleural thickening, pleural plaques, and nodular masses.

Differential Diagnosis:

- Lung Cancer: Distinguishes via location and immunohistochemical profile. - Lymphoma: Typically shows lymphadenopathy and different immunohistochemical markers. - Metastatic Disease: History and systemic involvement patterns help differentiate.

(Evidence: Strong 5)

Management

Surgical Interventions

First-Line:

Pleurectomy/Decortication: Recommended for patients with more superficial disease.

- Specifics: Non-incisional techniques are emerging as alternatives to reduce complications 1. - Contraindications: Extensive mediastinal involvement, poor cardiopulmonary reserve.

Extrapleural Pneumonectomy (EPP): Indicated for advanced, localized disease.

- Specifics: Involves removal of the lung, pericardium, diaphragm, and parietal pleura. - Contraindications: Significant comorbidities, poor lung function.

Second-Line:

Adjuvant Chemotherapy: Post-surgery to target residual disease.

- Drugs: Cisplatin + Pemetrexed (standard regimen). - Duration: Typically 6 cycles. - Monitoring: Regular blood counts, renal function, and tumor markers.

Radiation Therapy: Considered in selected cases, especially for palliation or localized disease control.

- Specifics: Intensity-modulated radiation therapy (IMRT) may be used. - Contraindications: Poor lung function, extensive disease.

Refractory / Specialist Escalation:

Clinical Trials: Participation in trials evaluating novel agents like tyrosine kinase inhibitors, histone deacetylase inhibitors, and proteosome inhibitors.

Supportive Care: Focus on symptom management, including pain control, respiratory support, and nutritional assistance.

(Evidence: Strong 5 7)

Complications

Acute Complications: Postoperative respiratory failure, infection, bleeding.

- Management Triggers: Fever, hypoxia, signs of sepsis.

Long-Term Complications: Recurrent pleural effusions, chronic pain, and potential long-term effects of chemotherapy.

- Management Triggers: Persistent symptoms, imaging evidence of recurrence. - Referral: Consider pulmonology, oncology, and palliative care specialists as needed 3.

Prognosis & Follow-Up

Prognosis for malignant pleural mesothelioma remains guarded, with median survival ranging from 12 to 24 months post-diagnosis, depending on stage and treatment modality. Key prognostic indicators include:

Stage at Diagnosis: Earlier stages generally correlate with better outcomes.

Histological Subtype: Epithelioid subtype typically has a better prognosis compared to sarcomatous or biphasic types.

Performance Status: Better performance status (e.g., ECOG 0-1) is associated with improved survival.

Follow-Up Intervals:

Initial: Every 3-6 months for the first 2 years.

Subsequent: Annually thereafter, focusing on imaging, tumor markers (e.g., mesothelin), and clinical assessment.

(Evidence: Moderate 2 5)

Special Populations

Elderly Patients: Consider functional status and comorbidities when selecting surgical interventions; less aggressive approaches may be warranted.

Comorbidities: Patients with significant cardiopulmonary disease may not tolerate extensive surgeries like EPP; pleurectomy/decortication may be preferred.

Pregnancy: Rare cases; management focuses on conservative approaches and multidisciplinary care to avoid teratogenic effects of aggressive treatments 5.

(Evidence: Moderate 5)

Key Recommendations

Diagnosis: Utilize thoracoscopy with immunohistochemical staining for definitive diagnosis 5.

Surgical Approach: Select pleurectomy/decortication for superficial disease and EPP for localized, advanced disease, considering non-incisional techniques to minimize complications 1 3.

Adjuvant Therapy: Post-surgery, use cisplatin + pemetrexed as the standard chemotherapy regimen 5.

Prognostic Assessment: Incorporate staging, histological subtype, and performance status in risk stratification 2.

Follow-Up: Implement regular follow-up with imaging and clinical assessments every 3-6 months initially, then annually 5.

Consider Multimodal Therapy: For select patients with favorable prognostic factors, consider trimodality therapy combining surgery, chemotherapy, and radiation 4.

Supportive Care: Integrate palliative care early to manage symptoms and improve quality of life 5.

Clinical Trials: Encourage participation in clinical trials for novel therapies in refractory cases 6.

Risk Assessment: Evaluate asbestos exposure history rigorously to inform prognosis and management strategies 5.

Special Considerations: Tailor treatment plans based on patient age, comorbidities, and pregnancy status 5.

(Evidence: Strong 5 1 2 3 4 6; Moderate 7)

References

1 Hasegawa S, Hashimoto M, Kondo N, Miyamoto Y. Non-incisional pleurectomy/decortication. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 2020. link 2 Leuzzi G, Rea F, Spaggiari L, Marulli G, Sperduti I, Alessandrini G et al.. Prognostic Score of Long-Term Survival After Surgery for Malignant Pleural Mesothelioma: A Multicenter Analysis. The Annals of thoracic surgery 2015. link 3 Burt BM, Cameron RB, Mollberg NM, Kosinski AS, Schipper PH, Shrager JB et al.. Malignant pleural mesothelioma and the Society of Thoracic Surgeons Database: an analysis of surgical morbidity and mortality. The Journal of thoracic and cardiovascular surgery 2014. link 4 Sugarbaker DJ, Wolf AS. Surgery for malignant pleural mesothelioma. Expert review of respiratory medicine 2010. link 5 Stahel RA, Felley-Bosco E, Opitz I, Weder W. Malignant pleural mesothelioma. Future oncology (London, England) 2009. link 6 Kaufman AJ, Pass HI. Current concepts in malignant pleural mesothelioma. Expert review of anticancer therapy 2008. link 7 Keller SM. Adjuvant therapy for malignant pleural mesothelioma. Chest surgery clinics of North America 1994. link

Malignant mesothelioma of pleura